Sanofi reported 10 positions worth $534.04M for the quarter ended Jun 30, 2026, up 59.0% on the prior quarter. It opened 2 new positions, added to 0, trimmed 0 and exited 1. Its largest holding is MeiraGTx Holdings plc at 30.9% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | -815.0K | -100.0% | $2.51M | Exited |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| ELDN Eledon Pharmaceuticals, Inc. | -815.0K | $2.51M | 0.747% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGTX MeiraGTx Holdings plc | Healthcare | 12.20M | $164.79M | 30.86% | 0 | 0.0% | Unchanged | 12.95% |
| 2 | INBX Inhibrx Biosciences, Inc. | Healthcare | 1.16M | $109.71M | 20.54% | 0 | 0.0% | Unchanged | 7.39% |
| 3 | NVAX Novavax Inc | Healthcare | 6.88M | $64.81M | 12.14% | 0 | 0.0% | Unchanged | 4.17% |
| 4 | ANAB Anaptysbio, Inc | Healthcare | 821.9K | $55.48M | 10.39% | 0 | 0.0% | Unchanged | 2.86% |
| 5 | ODTX Odyssey Therapeutics, Inc. | Healthcare | 1.99M | $37.27M | 6.98% | +1.99M | – | New | 4.16% |
| 6 | AGMB AgomAb Therapeutics NV | Healthcare | 2.78M | $36.12M | 6.76% | 0 | 0.0% | Unchanged | 22.26% |
| 7 | MPLT MapLight Therapeutics, Inc. | Healthcare | 912.0K | $32.69M | 6.12% | 0 | 0.0% | Unchanged | 2.01% |
| 8 | TRAX First Tracks Biotherapeutics, Inc. | Healthcare | 821.9K | $16.54M | 3.1% | +821.9K | – | New | 2.32% |
| 9 | IMRX Immuneering Corp | Healthcare | 2.71M | $13.52M | 2.53% | 0 | 0.0% | Unchanged | 4.19% |
| 10 | QTTB Q32 Bio Inc. | Healthcare | 244.1K | $3.11M | 0.582% | 0 | 0.0% | Unchanged | 1.03% |
Tip. Select a row to see that position’s full history at Sanofi.
As of its Q2 2026 13F filing, Sanofi’s five largest positions were MeiraGTx Holdings plc (MGTX) at 30.9%, Inhibrx Biosciences, Inc. (INBX) at 20.5%, Novavax Inc (NVAX) at 12.1%, Anaptysbio, Inc (ANAB) at 10.4%, Odyssey Therapeutics, Inc. (ODTX) at 7.0% of the reported portfolio.
Sanofi reported a 13F portfolio worth $534.04M across 10 positions for Q2 2026. That is up 59.0% from the previous quarter.
Its largest purchases by value were Odyssey Therapeutics, Inc. ($37.27M), First Tracks Biotherapeutics, Inc. ($16.54M). It opened 2 new positions.
Its largest sales by value were Eledon Pharmaceuticals, Inc. ($2.51M). It exited 1 positions entirely.
From the Form 13F-HR reports Sanofi files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.